Month: March 2024

In the bright spring of March, various flowers are blooming. The "13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association," hosted by the Chinese Medical Association and organized by the National Clinical Research Center for Hematologic Diseases - Peking University Institute of Hematology, was grandly held from March 1st to 2nd in Beijing. Hematopoietic stem cell transplantation is an important means of treating various hematologic diseases, and it is currently the most vigorous field in hematology at home and abroad. China's hematopoietic stem cell transplantation has also achieved remarkable results internationally, especially the "Beijing Protocol" established by Academician Xiaojun Huang, Director of Peking University Institute of Hematology and one of the chairpersons of this conference, has made outstanding contributions to the field of hematopoietic stem cell transplantation. This conference focused comprehensively on hematopoietic stem cell transplantation and conducted academic discussions from various aspects and forms. During the conference, Oncology Frontier - Hematology Frontier had the honor of inviting Academician Xiaojun Huang to share insights into the creation of the "Beijing Protocol" and point out the urgent problems and future directions in the field of hematopoietic stem cell transplantation.

With the arrival of spring, the 13th National Conference on Hematopoietic Stem Cell Transplantation of the Chinese Medical Association, hosted by the National Clinical Research Center for Hematologic Diseases and organized by Peking University Institute of Hematology, was grandly held in Beijing from March 1st to 2nd. This conference centered around the basic and clinical research of hematopoietic stem cell transplantation, covering multiple themes. During the conference, Oncology Frontier - Hematology Frontier had the honor to invite Professor Depei Wu from the First Affiliated Hospital of Soochow University for an interview, sharing challenges in the medical and health field and hopes for the younger generation.

In 2022, a groundbreaking study led by Professor Xiaojun Huang from Peking University Institute of Hematology, was published in the prestigious Journal of Hematology & Oncology. The study is titled "Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial." This research marks a pivotal advancement in the treatment of chronic myeloid leukemia (CML), particularly for patients harboring the T315I mutation, underscoring the potential of precision medicine in the fight against this challenging disease.

In 2023, a groundbreaking study spearheaded by Professor XiaoJun Huang from Peking University Institute of Hematology, made its debut in a prestigious international academic journal——Bone Marrow Transplantation. This pivotal research, entitled "Comparison of Haploidentical Hematopoietic Stem Cell Transplantation with Chemotherapy in Older Adults with Acute Myeloid Leukemia" offers a novel perspective on treatment efficacy for Acute Myeloid Leukemia (AML) in the elderly population. The study meticulously explores the viability and outcomes of using haploidentical donors for stem cell transplantation compared to traditional chemotherapy approaches, marking a significant advancement in the therapeutic landscape for older AML patients.

In July 2023, a groundbreaking study led by Professor Xiaojun Huang from Peking University Institute of Hematology was published in a prestigious academic journal ——Annals of Hematolog. The study, titled "Impacts of Early Therapy Response, Interval to Therapy Interruption, and Cumulative Therapy Interruption Duration on Outcome of Ibrutinib Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia" marks a pivotal advancement in the treatment and management of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This research, conducted in collaboration with experts like Shenmiao Yang, Nan Li, Rong Zhu, Yu Feng, Jianmin Zhuo, and the internationally renowned hematologist Robert Peter Gale, leverages data from a multicenter phase 3 study to enhance our understanding of ibrutinib therapy in CLL/SLL, particularly regarding the effects of therapy interruptions on patient outcomes.

In July 2023, a significant study led by Professor Xiaojun Huang from Peking University Institute of Hematology was published in Leukemia, focusing on chronic myeloid leukemia (CML) treatment with imatinib. This research introduced and validated a predictive scoring system to forecast molecular responses in CML patients. The study, involving an external validation on a cohort of 2,184 patients, demonstrated the efficacy of this model in stratifying patients into risk categories for more personalized treatment approaches. Through rigorous statistical analysis, including ROC curves and decision curve analyses, Huang and his team's work stands as a pivotal contribution to optimizing CML management and enhancing patient care outcomes.